Hepatitis C virus escape studies for human antibody AR3A reveals a high barrier to resistance and novel insights on viral antibody evasion mechanisms
Journal of virology, 2018.
Yearly ∼2 million people become hepatitis C virus (HCV) infected, resulting in elevated life-time risk for severe liver-related chronic illnesses. Characterizing epitopes of broadly neutralizing antibodies (NAbs), such as AR3A, is critical to guide vaccine development. Previously identified alanine substitutions reducing AR3A binding to e...More
Full Text (Upload PDF)
PPT (Upload PPT)